Chris Murphy

Chris Murphy is an accomplished biopharmaceutical consultant with extensive experience in research and development, having held leadership positions at several prominent companies. Most recently, Chris has been serving as an independent consultant since October 2023. Prior roles include Vice President at Adiso Therapeutics and Bacainn Therapeutics, both Morningside Portfolio Companies, where significant contributions were made to R&D initiatives. Chris has demonstrated expertise in pharmacology and microbiology through previous roles as Sr. Director of Pharmacology at Kaleido Biosciences and Director of Pharmacology at Cubist Pharmaceuticals, as well as directing microbiology departments in earlier positions. Education includes a Postdoctoral degree in Bacterial Genetics from Harvard Medical School, a Ph.D. in Microbiology and Molecular Genetics from the University of Notre Dame, and a Bachelor’s degree in Microbiology and Immunology from McGill University.